Research on the causes of death associated with combined effects of HBV and HCV infection in patients with acquired immunodeficiency syndrome
10.3760/cma.j.issn.1007-3418.2018.07.003
- VernacularTitle: 合并HBV、HCV感染对获得性免疫缺陷综合征患者死亡原因影响的研究
- Author:
Pengle GUO
1
;
Weiping CAI
;
Xiejie CHEN
;
Haolan HE
;
Fengyu HU
;
Xiaoping TANG
;
Linghua LI
Author Information
1. Department of Infectious Diseases, Guangzhou Eighth People’s Hospital, Guangzhou 510060, China
- Publication Type:Journal Article
- Keywords:
Acquired immunedeficiency syndrome;
End-stage liver diseases;
Cause of death;
Human immunodeficiency virus;
Hepatitis C virus;
Hepatitis B virus
- From:
Chinese Journal of Hepatology
2018;26(7):495-498
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the combined effects of hepatitis B virus and hepatitis C virus (HBV/HCV) infection on the cause of death in patients with acquired immunodeficiency syndrome (AIDS).
Methods:The causes of death of 111 cases of AIDS with HBV/HCV (combined infection group) and 210 AIDS patients (single infection group) admitted to our hospital from 2012 to 2016 data were compared using chi-square test.
Results:There was no statistically significant difference in gender composition and age in the combined infection groups (P > 0.05). The main causes of death in the combined infection group were severe pneumonia (44.1%), end-stage liver disease (18.9%), and central nervous system infection (14.4%). The main causes of death in the single infection group were severe pneumonia (47.6%) and central nervous system infection (14.3%) and tumor (13.3%). There was no case of end-stage liver disease. The ratio of end-stage liver disease in the former group was significantly higher than that in the latter group (χ2 = 42.511, P < 0.001). The main cause of death in 12 HIV/HBV/HCV triple-infected patients was end-stage liver disease, accounting for 41.7%, which was significantly higher than 18.9% of end-stage liver disease in HIV/HBV or HIV/HCV dual infection (99 cases). And the difference was statistically significant (χ2 = 4.539, P = 0.033); however, the ratio of end-stage liver disease in 50 HIV/HBV co-infected patients and 49 HIV/HCV co-infected patients was 16.0% vs. 16.3%, respectively, and the difference was not statistically significant (χ2 = 0.002, P = 0.965). In the co-infected group, 36 patients had CD4+ cell counts >100/μl, the primary cause of death was end-stage liver disease, accounting for 38.2%. 75 patients with CD4+ ≤ 100/μl died due to end-stage liver disease, accounting for 9.3% and the difference was statistically significant (χ2 = 13.852, P < 0.05).
Conclusion:End-stage liver disease is the main cause of death in patients with AIDS combined with HBV or HCV, especially triplet infection and CD4+ cell count > 100/μl. An early diagnosis and treatment of HBV or HCV infection should commence as soon as possible.
